BIOA Healthcare

BioAge Labs, Inc.

$5.96+2.76%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 273.5M USD
Enterprise value: -94.0M USD
Full-time employees: 60

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.08 vs a peer median of 0.63)bigger price swings (beta 1.08 vs peers 0.63)

Ranks #443 of 1,157 healthcare companies (top 39%)

See how it ranks against its peers

Worth knowing

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.
BioAge Labs's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.BioAge Labs's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, BioAge Labs looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss, from a small base ($10M of revenue over 12 months).
Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -1026%).

StockQuotient Score

57/ 100

Oct 5 58 → Nov 4 57 (-1)

Valuation

Is the price right?

33/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Share count up 3.2% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-34.5%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yieldUnavailable

Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0401 · MAD: 0.0401

Free cash flow yield-32.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield137.1%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

95/100

Strong

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth168.1%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 10.15Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

5/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-1026.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-23.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.75Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-27.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.22Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-25.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.08

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.35Sector median: 0.6250 · MAD: 0.3380

Current ratio17.19×

SEC filings · latest balance sheetReported value33% base weight · Z-score 10.54Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.01×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.04Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about BioAge Labs

Is BioAge Labs getting weaker?: Its latest SEC filing (Aug 5, 2026) got weaker in some ways: share count up 3.2%. Its overall score is unchanged at 57/100 since Oct 28, 2026.
How is BioAge Labs valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -34.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -34.5% vs peers 1.5% (weaker than 100% of peers).
Is BioAge Labs growing?: Yes, faster than most of its peers. Growth scores 95/100 against 1,393 healthcare peers. Revenue growth 168.1% vs a peer median of 6.1% (stronger than 95% of peers).Revenue growth 168.1% vs peers 6.1% (stronger than 95% of peers).
How profitable is BioAge Labs?: Less profitable than most of its peers. Profitability scores 5/100 against 1,393 healthcare peers. Operating margin -1026.3% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -1026.3% vs peers 7.1% (weaker than 100% of peers).
How risky is BioAge Labs?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 17.19× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 17.19× vs peers 2.59× (stronger than 95% of peers). Beta 1.08 vs a peer median of 0.63 (weaker than 75% of peers).Beta 1.08 vs peers 0.63 (weaker than 75% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 3.2% (existing holders diluted)

Worth watching: BioAge Labs is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	10.3M USD	10.4M USD	+0.4%
Net income (12 months)	−89.9M USD	−94.5M USD	+5.0%
Operating margin	-985.9%	-1026.3%	−40.3 pts
Free cash flow (12 months)	−88.6M USD	−88.1M USD	−0.6%
Cash	241.8M USD	74.0M USD	−69.4%
Shares outstanding	44.5M	45.9M	+3.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Operating margin	—	—	-1031.5%	—
Net margin	—	—	-896.1%	—
Return on assets (ROA)	-246.3%	-19.8%	-27.3%	▼ 7.5 pts
Return on equity (ROE)	—	-22.0%	-29.6%	▼ 7.6 pts
Free cash flow margin	—	—	-915.5%	—
Current ratio	0.44×	12.86×	14.24×	▲ 11%
Debt to equity	—	0.03×	0.01×	▼ 63%
Interest coverage	-6.21×	-33.04×	-133.11×	▼ 303%

BIOA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.08 vs a peer median of 0.63)bigger price swings (beta 1.08 vs peers 0.63)

Ranks #443 of 1,157 healthcare companies (top 39%)

See how it ranks against its peers

Worth knowing

Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

BioAge Labs's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.BioAge Labs's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, BioAge Labs looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss, from a small base ($10M of revenue over 12 months).

Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -1026%).

Questions investors ask about BioAge Labs

Is BioAge Labs getting weaker?

Its latest SEC filing (Aug 5, 2026) got weaker in some ways: share count up 3.2%. Its overall score is unchanged at 57/100 since Oct 28, 2026.

How is BioAge Labs valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 33/100 against 1,393 healthcare peers. Earnings yield -34.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -34.5% vs peers 1.5% (weaker than 100% of peers).

Is BioAge Labs growing?

Yes, faster than most of its peers. Growth scores 95/100 against 1,393 healthcare peers. Revenue growth 168.1% vs a peer median of 6.1% (stronger than 95% of peers).Revenue growth 168.1% vs peers 6.1% (stronger than 95% of peers).

How profitable is BioAge Labs?

Less profitable than most of its peers. Profitability scores 5/100 against 1,393 healthcare peers. Operating margin -1026.3% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -1026.3% vs peers 7.1% (weaker than 100% of peers).

How risky is BioAge Labs?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 17.19× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 17.19× vs peers 2.59× (stronger than 95% of peers). Beta 1.08 vs a peer median of 0.63 (weaker than 75% of peers).Beta 1.08 vs peers 0.63 (weaker than 75% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

10.3M USD

10.4M USD

+0.4%

Net income (12 months)

−89.9M USD

−94.5M USD

+5.0%

Operating margin

-985.9%

-1026.3%

−40.3 pts

Free cash flow (12 months)

−88.6M USD

−88.1M USD

−0.6%

Cash

241.8M USD

74.0M USD

−69.4%

Shares outstanding

44.5M

45.9M

+3.2%

Key ratios

FY 2023

FY 2024

FY 2025

Change

Operating margin

—

-1031.5%

—

Net margin

—

-896.1%

—

Return on assets (ROA)

-246.3%

-19.8%

-27.3%

▼ 7.5 pts

Return on equity (ROE)

—

-22.0%

-29.6%

▼ 7.6 pts

Free cash flow margin

—

-915.5%

—

Current ratio

0.44×

12.86×

14.24×

▲ 11%

Debt to equity

—

0.03×

0.01×

▼ 63%

Interest coverage

-6.21×

-33.04×

-133.11×

▼ 303%